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Abstract
Background: Inappropriate sinus tachycardia (IST) is an uncommon disorder characte-
rized by an exaggerated heart rate (HR). It is mostly treated with b-blockers or verapamil
leaving the sinus node modulation for refractory cases. Ivabradine, a pure HR lowering agent,
has proven anti-anginal efficiency linked to the If current inhibition. We conducted a small
prospective experience investigating its efficacy in IST.
Methods: Four women exhibiting sinus rhythm with a resting HR ≥ 100 bpm and an
average HR ≥ 90 bpm (Holter monitoring) were followed for three months. Structural heart
disease and other causes of tachycardia were discarded. Electrocardiographic, Holter
monitoring, exercise tolerance and quality of life determinations were performed. Ivabradine
was initiated at 5 mg (bid) and increased to 7.5 mg (bid) after one week.
Results: All patients (mean age 33.7 years) presented a typical history of effort intolerance,
palpitations and tachycardia. Resting HR (bpm) was decreased: 106.5 ± 3 to 88.5 ± 2 (week 1),
to 77.0 ± 3 (week 2) and to 73.7 ± 13 (month 3). Reductions (Holter monitoring) of the
maximum, average and minimum HR (beats) were: 152.0 ± 19 to 128.5 ± 18; 96.0 ± 1.4 to
73 ± 3.2 and 63.2 ± 6 to 48.2 ± 3. Total exercise time was amplified (555 ± 99 to 679 ± 90 s)
and quality of life improved.
Conclusions: IST causes an elevated HR and its control is the treatment objective. If future
data confirm our results, ivabradine could be used for this purpose. More information is
necessary in order to define its role: initial option, second step (b-blockers non-responders or
intolerants) or combined (refractory cases). (Cardiol J 2010; 17, 2: 166–171)
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Introduction
Inappropriate sinus tachycardia (IST) is an
uncommon form of tachyarrhythmia characterized
by an exaggerated resting heart rate (HR) and/or
an increased HR response to a minimal effort [1].
Its aetiology remains not well established but it has
been attributed to an augmentation in the intrinsic
sinus rate, associated with a beta-adrenergic hyper-
sensitivity and a marked depressed response to the
vagal reflex [2, 3]. In addition, IST has been linked
to an eventual immunoregulatory dysfunction
caused by anti-beta receptor antibodies [4]. This
entity is defined as a nonparoxysmal tachyarrhyth-
mia with a resting daytime HR higher than 100 beats
per minute (bpm) or an average heart rate higher
than 90 bpm in a 24 hours Holter monitoring with
a preserved P wave morphology [1]. IST is found
more often in women (4:1). Its clinical features vary
from transitory episodes of palpitations to an inces-
sant tachycardia. In this setting, patients may
present dyspnoea, fatigue, thoracic pain or even
syncope [5, 6]. Its standard therapy includes a beta-
blocker agent or verapamil leaving the modulation
of the sinus node for refractory cases [5, 7, 8].
Ivabradine is a selective inhibitor of the If current
that contributes to the sinus node automaticity. This
means it can reduce HR without disturbing the inotro-
pic state [9]. Its effectiveness as an anti-anginal agent is
well established [10–12] but its utility in the specific
field of IST has not been previously investigated. Iso-
lated experiences suggest that ivabradine may have
a beneficial effect in this context [13–16].
We present a very small prospective experience
with four patients suffering from IST who were treat-
ed with ivabradine. A three month-long follow-up was
conducted implementing electrocardiographic, Hol-
ter monitoring, exercise tolerance and quality of life
assessments. To the best of our knowledge, this is
the first prospective experience evaluating the effi-
cacy of ivabradine in patients with IST.
Methods
Objective
We wanted to investigate the chronotropic ef-
fects of ivabradine in patients fulfilling the criteria
of IST. For this purpose, we followed the same dia-
gnostic requirements used to assess the preva-
lence of this disorder in the OPERA study [1]. Our
four patients exhibited sinus rhythm with a resting
HR ≥ 100 bpm in both supine or sitting position and
an average HR ≥ 90 bpm in a 24 hours Holter mon-
itoring [1].
Patients
The studied patients were four female outpa-
tients referred to our cardiology unit by their family
doctors during 2008. All four presented a typical
history of marked effort intolerance, early fatigue or
dyspnoea, palpitations and exaggerated tachycardia.
No previous treatment (beta-blocker agents or
verapamil) had been administered to these patients.
Structural cardiac disease was ruled out (nor-
mal echocardiogram) and other causes of acceler-
ated HR like anaemia, hyperthyroidism, diabetes,
orthostatic hypotension, drugs, etc., were also dis-
carded. After the confirmation of the diagnosis (Hol-
ter monitoring), a fatigue-limited treadmill exercise
tolerance test (ETT) using the standard Bruce pro-
tocol was performed. In addition, the subjective
impact of the disease was addressed by a short qual-
ity of life questionnaire which was specifically de-
signed for this purpose (Fig. 1).
Ivabradine was provided by the hospital phar-
macy. The study was approved by the local bioeth-
ical committee and all patients gave their informed
consent.
Methodology
Our study was a prospective follow up of three
months and ivabradine was started at an initial dai-
ly dose of 5 mg bid. This was increased to 7.5 mg
bid after the first week and continued until the end
Have you suffered from tachycardia ___________
episodes in recent weeks?
Have you suffered from palpitation ___________
episodes in recent weeks?
Have you suffered a disproportionate ___________
fatigue during a routine effort
in recent weeks?
Have you suffered from thoracic ___________
pain episodes in recent weeks?
Have you suffered from dizziness ___________
episodes in recent weeks?
Have you had the sensation of being ___________
permanently tired in recent weeks?
Figure 1. Quality of life questionnaire. The question-
naire was answered assigning a number (from 1 to 5) to
each question (baseline and three month follow-up).
Frequency of symptoms was described according to
the following scale (points): No symptoms — 1; Occa-
sional occurrence — 2; Repeated occurrence — 3; Fre-
quent occurrence — 4; Very frequent occurrence — 5.
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of the follow-up. Patients were evaluated at weeks
1, 2, 3 and 4 and during the second and third months.
At the end of the third month, a new evaluation was
made repeating the Holter monitoring, the ETT and
the quality of life questionnaire. Data is presented
as mean values ± standard deviation (SD) and two
sided 95% confidence interval (CI); variation is ex-
pressed as percentage (%). CI is included in the
tables in spite of the reduced sample size.
Results
The mean age of our four patients was 33.7
years (21 to 44) and all were Caucasian. None of
them were smokers and their mean heights and
weights were 161 ± 2.6 cm and 60 ± 9.7 kg, re-
spectively. Mean left ventricular ejection fraction
and left ventricular diastolic diameter were normal:
69.2% (65–72) and 45.2 mm (38–53), respectively.
Resting HR (sitting position) was significantly
reduced after the first week using a daily dose of
5 mg bid (106.5 ± 3 to 88.5 ± 2 bpm). A significant
reduction was observed after the second week, hav-
ing increased the dose to 7.5 mg bid (88.5 ± 2 to
77.0 ± 3 bpm). Subsequently, HR remained stable
until the end of the follow-up (77.0 ± 3 to 73.7 ±
± 13 bpm). Considering the baseline HR, ivabra-
dine induced a dramatic reduction at three months
follow-up (106.5 ± 3 to 73.7 ± 13 bpm; Table 1). On
the other hand, a slight increase of blood pressure
measurements (baseline-three month) was observed:
112 ± 12.6 to 120 ± 11.5 mm Hg for systolic blood
pressure and from 67.5 ± 9 to 70 ± 8 mm Hg for
diastolic blood pressure.
The benefit of the therapy was also confirmed
in the 24 hours Holter monitoring, where the re-
duction of the HR (maximum, average and mini-
mum) was evident (Table 2). Maximum and aver-
age HR significantly decreased (152.0 ± 19 to
128.5 ± 18 and 96.0 ± 1.4 to 73 ± 3.2 beats,
respectively). Minimum HR was also reduced and
ivabradine did not provoke excessive bradycardia
(63.2 ± 6 to 48.2 ± 3 beats).
In addition, treatment with ivabradine was ac-
companied by an increased effort tolerance which
was demonstrated as longer total exercise time
(time to fatigue: 555 ± 99 to 679 ± 90 s) and
a greater intensity of effort (10.68 ± 1.9 to 13.15 ±
± 1.7 METS). These positive changes were ob-
tained departing from a lower baseline HR and
reaching a lower peak exercise HR too. Accord-
ing to this, a reduction in the maximal theoretic
heart rate (age-predicted maximal heart rate) was
observed (Table 3).
Table 1. Changes in heart rate over a three month follow-up.
Visit HR [bpm] Range HR [bpm] 95% CI Variation (%)
Baseline 106.5±3 103–110 101.55–111.4
Week 1 88.5±2 87–91 85.45–91.55 –16.9±2.7
Week 2 77.0±3 74–80 71.49–82.51 –27.7±3.8
Week 3 79.7±3 77–84 74.82–84.68 –25.0±5.0
Week 4 77.5±7 67–82 66.05–87.95 –27.7±5.6
Month 2 74.0±7 64–79 63.29–85.71 –30.1±5.5
Month 3 73.7±13 55–85 52.83–94.67 –30.9±11.4
CI — confidence interval; HR — heart rate
Table 2. Changes in heart rate assessed by Holter monitoring.
Determination Value [bpm] Range [bpm] 95% CI Variation (%)
Baseline maximum HR 152.0±19 127–168 122.0–182.0
Month 3 maximum HR 128.5±18 106–150 99.17–157.8 –15.5±4.6
Baseline minimum HR 63.2±6 57–69 54.21–72.29
Month 3 minimum HR 48.2±3 46–52 44.07–52.43 –23.1±9.9
Baseline average HR 96.0±1 95–98 93.7–98.2
Month 3 average HR 73.0±3 69–77 67.8–78.2 –23.9±3.6
CI — confidence interval; HR — heart rate
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The subjective perception of the disorder was
also improved (13.25 ± 0.9 to 9.25 ± 2.7 points;
Fig. 1) and no side effects from the use of ivabra-
dine were detected.
Discussion
IST is a diagnosis of exclusion and it is neces-
sary to rule out other causes of sinus tachycardia
before considering whether it is present. This dis-
order was initially thought to be rare, but its prev-
alence in the general population seems to be high-
er than other arrhythmias such as Wolf-Parkinson-
-White syndrome or ectopic atrial tachycardia. This
point was addressed in 604 patients (aged 40 to 59)
belonging to the OPERA study (Oulu Project Elu-
cidating Risk of Atherosclerosis) where IST was
detected in seven subjects (1.16%). The prognosis
of IST appears to be benign since none of the 11
subjects (seven OPERA patients and four extra
cases) who attended a mean follow up of 6 ± 2.4
years developed any clinical or echocardiographic
evidence of deterioration, although the elevated HR
was maintained [1].
This inappropriately high HR is responsible for
the clinical manifestations of the disease. Its reduc-
tion is the objective of the treatment. Until now, it
has been mostly treated with beta-blocker agents
or verapamil leaving the modulation of the sinus
node for refractory cases [5, 7, 8].
Selective inhibition of the If current confers on
ivabradine the ability to reduce HR without com-
promising myocardial contractility. Ivabradine has
a dose-dependent effect on both resting HR and HR
during exercise, something which has greater sig-
nificance at a higher HR [9].
Ivabradine has proven anti-ischemic efficacy
compared to a placebo [10], atenolol [11] or amlo-
dipine [12]. Its effectiveness comparative to
atenolol was revealed in a double-blind randomized
study (the INITIATIVE trial) in patients with chron-
ic stable angina. This involved 939 patients random-
ized to either 5 mg bid of ivabradine or 50 mg od of
atenolol. At four weeks, both agents were increased
(if tolerated) to 7.5 mg bid and 100 mg od respec-
tively. Ivabradine reduced resting HR in a way com-
parable with atenolol and at four weeks, resulted
non-inferior in all primary and secondary end-points
(time to onset of angina, time to limiting angina and
time to onset of 1 mm ST-segment depression) [11].
In another double-blind study, ivabradine (7.5 mg
bid) was compared with amlodipine (10 mg od) in
patients with stable angina. A significant reduction
in HR was observed in the ivabradine group (at rest
and during exercise), something which did not hap-
pen in the amlodipine group. A non-significant dif-
ference between the two groups was detected in the
primary end-point (change in total exercise dura-
tion at three months) and both agents exhibited
a similar improvement in terms of the frequency of
anginal episodes [12]. In a further double-blind
trial, 889 patients with stable angina treated with
atenolol (50 mg/day) were randomized to receive
ivabradine 5 mg bid for two months and then augment-
ed to 7.5 mg bid for a supplementary two months or
a placebo. Primary end-point was change in total ex-
ercise duration at four months and the ivabradine
group had better results. Ivabradine in combination
with atenolol was well tolerated and an additional re-
duction of HR was observed (at rest and during exer-
cise). Only 1.1% of patients were removed due to si-
nus bradycardia in the ivabradine group [17].
Table 3. Changes in exercise tolerance test criteria.
Exercise treadmill test Value Range 95% CI Variation (%)
Baseline pre-test HR [bpm] 114.8±10 103–127 99.03–130.5
Month 3 pre-test HR [bpm] 98.7±13 85–112 77.67–119.8 –14.13 ± 6
Baseline time of exercise [s] 555±99 450–690 396–713
Month 3 time of exercise [s] 679±90 571–780 535–823 24.6 ± 24
Baseline effort developed [METS] 10.68±1.9 9.2–13.5 7.62–13.73
Month 3 effort developed [METS] 13.15±1.7 11.0–15.2 10.39–15.91 24.5 ± 17
Baseline highest HR [bpm] 178.5±15 162–193 154.1–202.9
Month 3 highest HR [bpm] 165.0±25 134–187 124.8–205.1 –7.8 ± 8
Baseline MTHR (%) 93.5±6 87–100 84.4–102.5
Month 3 MTHR (%) 87.2±13 69–100 66.3–108.2 –7.04 ± 9
CI — confidence interval; HR — heart rate; MTHR — maximal theoretic heart rate (age-predicted maximal heart rate)
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Published information concerning the use of
ivabradine as a pure HR lowering agent in patients
not suffering from chronic stable angina has been,
until now, very limited. It was successfully used in
a female patient (aged 21) with postural orthostatic
tachycardia syndrome in the context of a chronic
fatigue syndrome [13]. The same success was ob-
served in another woman with postural orthostatic
tachycardia syndrome (aged 44) with a dual cham-
ber pacemaker [14]. The favorable effect of ivabra-
dine was also reported in two female patients (ages
29 and 30) with IST but intolerant to beta-blockers
(fatigue and hypotension) [15, 16]. In the first case,
the average 24 hours HR was reduced from 101 bpm
to 76 bpm using 15 mg daily of ivabradine [15]. In
the second case, resting HR was decreased from
100 bpm to 63 bpm with the same dose [16]. In ad-
dition, ivabradine was satisfactorily used in 26 heart
transplant recipients with permanent sinus tachy-
cardia secondary to cardiac denervation. Resting
HR was lowered from 106.3 ± 9.1 to 82.2 ± 6.3 bpm
after three weeks of treatment (5 mg bid) [18].
Generally, beta-blockers are prescribed as the
first choice in the therapy of IST. But despite their
efficacy, their potential side effects could represent
a limitation (fatigue, induced hypotension, bron-
chospasm, reduced libido, etc) [19]. If beta-block-
ers are not well tolerated, verapamil is usually the
second option, but its chronotrophic control tends
to be more modest. On the other hand, sinus node
modulation is an effective (though invasive)
procedure which is reserved for unmanageable cas-
es [5, 7, 8].
In our modest study, ivabradine exhibited
a dose-dependent effect on both resting HR and HR
during exercise. In consequence, our patients were
able to develop a higher effort tolerance. The sub-
jective perception of the disease was attenuated and
ivabradine was well tolerated (no side effects).
Taking this into account, it seems reasonable
to assume that ivabradine may have a therapeutic
role for IST. One possibility is to use it as a valid
initial choice or as an alternative to beta-blockers
for non-responders or those who are intolerant. We
should also consider a possible combination with
a beta-blocker agent as a previous step in order to
avoid an invasive modulation of the sinus node.
To the best of our knowledge, this is the first
prospective experience evaluating the chronotroph-
ic efficacy of ivabradine in this setting. Although this
is a very limited study, we believe that ivabradine
could be an effective and safe therapeutic choice for
patients with IST. A larger study is needed to clar-
ify its role.
Conclusions
IST is a relatively uncommon disorder that
causes an elevated HR. Accordingly, chronotro-
phic control is the objective of the treatment. In our
very limited experience, ivabradine has proved to
be an effective and safe way of reducing HR in pa-
tients with IST. So, if future data confirms our re-
sults, it is highly likely that ivabradine will be of use
for this purpose. More information is needed in or-
der to define its role: initial therapy, second step
(beta-blockers non-responders or intolerants) or as
a combination of both in more severe cases.
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